Scarica l'app Stockscreener
8.71
1.99%
0.17
Precedente Chiudi:
$8.54
Aprire:
$8.61
Volume 24 ore:
1.06M
Relative Volume:
1.88
Capitalizzazione di mercato:
$590.09M
Reddito:
$568.09M
Utile/perdita netta:
$27.27M
Rapporto P/E:
26.59
EPS:
0.3276
Flusso di cassa netto:
$71.41M
1 W Prestazione:
+0.35%
1M Prestazione:
-18.06%
6M Prestazione:
+13.12%
1 anno Prestazione:
+35.46%
Intervallo 1D:
$8.61
$8.86
Intervallo di 1 settimana:
$8.39
$8.86
Portata 52W:
$5.81
$11.25
Bioventus Inc Stock (BVS) Company Profile
Nome
Bioventus Inc
Settore
Industria
Telefono
(919) 474-6700
Indirizzo
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
8.71 | 590.09M | 568.09M | 27.27M | 71.41M | 0.3276 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | CJS Securities | Market Outperform |
| 2026-02-09 | Iniziato | Barrington Research | Outperform |
| 2025-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-12-07 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2022-11-22 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-11-09 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Downgrade | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Iniziato | Craig Hallum | Buy |
| 2021-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2021-11-10 | Ripresa | JP Morgan | Overweight |
| 2021-07-01 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-08 | Iniziato | Canaccord Genuity | Buy |
| 2021-03-08 | Iniziato | Goldman | Buy |
| 2021-03-08 | Iniziato | JP Morgan | Overweight |
| 2021-03-08 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Bioventus Inc Borsa (BVS) Ultime notizie
Precision Trading with Bioventus Inc. (BVS) Risk Zones - Stock Traders Daily
Bioventus Inc (BVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bioventus Inc (BVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bioventus Inc (BVS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bioventus Inc (BVS) Institutional Confidence - TradingKey
Bioventus Inc (BVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bioventus Inc (BVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bioventus Inc (BVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bioventus Inc (BVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bioventus Inc (BVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
EBIT per share of Bioventus, Inc. Class A – TRADEGATE:4B8 - TradingView
After tax other income/expense of Bioventus, Inc. Class A – TRADEGATE:4B8 - TradingView
Bioventus, Inc. Class A Statistics – TRADEGATE:4B8 - TradingView
Bioventus, Inc. Class A Trade Ideas — TRADEGATE:4B8 - TradingView
BVS Maintained by Canaccord Genuity -- Price Target Stays at $15 - GuruFocus
Canaccord reiterates Bioventus stock rating on growth strategy - Investing.com
Canaccord reiterates Bioventus stock rating on growth strategy By Investing.com - Investing.com Canada
Bioventus Inc. (BVS) Q1 2026 Earnings: Strong EPS Beat Despite Stock DeclineEarnings Miss Streak - newsline.com
Bioventus highlights PNS, PRP growth as cash flow improves and debt falls - MSN
Are Investors Undervaluing Bioventus (BVS) Right Now? - Yahoo Finance
Bioventus (BVS) Edges Lower as Stock Tests Support ZoneGamma Squeeze - newsline.com
Bioventus Highlights PNS, PRP Growth as Cash Flow Improves and Debt Falls - sharewise.com
Bioventus (BVS) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Bioventus Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Technical Reactions to BVS Trends in Macro Strategies - Stock Traders Daily
BVS SEC FilingsBioventus Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Bioventus (BVS) director and 10% owner reports RSU grant and vesting-related share exercise - Stock Titan
Bioventus (NASDAQ: BVS) director Sutter awarded 25,146 RSUs and exercises 32,282 shares - Stock Titan
Bioventus (BVS) director granted RSUs and exercises prior awards - Stock Titan
Bioventus (BVS) director exercises RSUs and holds 148,892 shares - Stock Titan
Bioventus (BVS) director receives 25,146 RSUs and converts 32,282 into shares - Stock Titan
Bioventus (BVS) director McMurry-Heath gains shares via RSU vesting and new grant - Stock Titan
[Form 4] Bioventus Inc. Insider Trading Activity - Stock Titan
Bioventus (BVS) director Hawkins granted 30,994 RSUs and exercises 39,789 into shares - Stock Titan
Bioventus (BVS) director granted 25,146 RSUs and exercises 32,282 into shares - Stock Titan
Bioventus (BVS) director Pat Beyer receives 25,146 RSUs and converts 32,282 into Class A shares - Stock Titan
Bioventus Q1 2026 slides: earnings beat drives guidance raise - Investing.com
Bioventus Shareholders Back Directors and Auditor at 2026 Meeting - TipRanks
Bioventus (BVS) 2026 meeting re-elects full board and ratifies auditor - Stock Titan
Bioventus (BVS) Q1 2026 Earnings Transcript - AOL.com
After Plunging 22% in 4 Weeks, Here's Why the Trend Might Reverse for Bioventus (BVS) - Yahoo Finance
Bioventus (BVS) may find a bottom soon, here's why you should buy the stock now - MSN
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference - The Manila Times
Watch Bioventus' CFO in a live Goldman Sachs healthcare fireside chat - Stock Titan
Transcript: Bioventus Q1 2026 Earnings Conference Call - Benzinga
BVS Q1 2026 Earnings: Strong EPS Beat Overshadowed by Market SkepticismAnalyst Coverage Count - The Legal Advocate
BVS Q1 2026 Earnings: EPS Beats Estimates by 52.3% Despite Stock DeclineEarnings Analysis - The Legal Advocate
Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - sharewise.com
Bioventus Inc. (BVS) Holds Steady Near Support as Consolidation PersistsBlock Trade Flow - newsline.com
Number of shareholders of Bioventus Inc. – NASDAQ:BVS - TradingView
Is Bioventus (BVS) stock undervalued right now? - MSN
Bioventus Inc Azioni (BVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bioventus Inc Azioni (BVS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SUTTER MARTIN P | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
117,523 |
| STALNECKER SUSAN M | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
138,239 |
| NOHRA GUY P | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
148,892 |
| NEELS GUIDO J | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
117,523 |
| McMurry-Heath Michelle | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
77,279 |
| Ladone Mary Kay | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
111,263 |
| HAWKINS WILLIAM A | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
39,789 |
0 |
297,640 |
| Cowdy Philip G. | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
43,982 |
| Beyer Pat | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
108,718 |
| Singleton Mark Leonard | SVP & CFO |
Apr 10 '26 |
Option Exercise |
0.00 |
13,000 |
0 |
182,981 |
0.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):